Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 4Endocrine 4CNS 3NET 2Gastrointestinal 1

Conditions

Brain Neoplasms 593Glioblastoma 573Glioma 298Central Nervous System Neoplasms 208Gliosarcoma 177Neuroblastoma 175Astrocytoma 174Oligodendroglioma 112Carcinoma, Non-Small-Cell Lung 92Medulloblastoma 80Breast Neoplasms 74Ependymoma 61Sarcoma 60Meningioma 60Neoplasm Metastasis 57Recurrence 56Melanoma 56Neoplasms 51Lung Neoplasms 48Neurofibromatosis 1 43Meningeal Carcinomatosis 40Osteosarcoma 39Pheochromocytoma 38Rhabdomyosarcoma 37Wilms Tumor 36Paraganglioma 35Lymphoma, Non-Hodgkin 32Neuroectodermal Tumors, Primitive, Peripheral 29Lymphoma 27Sarcoma, Ewing 26

Interventions

belzutifan 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × von Hippel-Lindau Disease × CNS × Clear all
NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07167329 2025-09-11

BELIEVE-VHL

AC Camargo Cancer Center

Phase 2 Recruiting
100 enrolled
CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT01266070 2017-02-13

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 5 charts
CNS

von Hippel-Lindau Disease, Central Nervous System Neoplasms, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡